Nov 2, 2026 earnings call — BWXT highlights nuclear wins and capacity expansions
BWXT reported third quarter revenue of $953 million, up 10% year-over-year.
Revenue $1.0B (est $1.0B) · EPS $1.26 (est $1.18)
Key quotes
"On HPDU, as part of our $1.6 billion contract to produce 300 metric tons of high-purity depleted uranium annually, we initiated construction of a new large-scale facility in Jonesborough, Tennessee, that will drive meaningful revenue growth in the fourth quarter and through 2027."
"And lastly, we entered into a multiyear agreement to supply an initial allocation of 1 metric ton of TRISO fuel to Antares, our first large-scale commercial customer."
"The expansion increases our heavy component manufacturing capacity by about 50% and will improve operating efficiency and throughput as we execute on our deep backlog associated with CANDU life extensions and SMR projects and other new awards."
Analyst Q&A 14
Why government margins rose
Q (Matthew Akers · BNP Paribas): Analyst asked what drove the strong Government Operations margins. He also asked whether the PCG deal added backlog, how it runs off, and how it fits with capacity plans.
A: Management said margins improved because of higher efficiency and better-managed volume in the naval nuclear work. They said the PCG deal brought close to $500 million in backlog that will burn off over time. They plan to use the site's unutilized capacity, with modest CapEx, to do commercial work.
"I think when you get down to it and really what's happening is we're seeing a substantial increase in the efficiency of the volume of the work that we performed specifically in our naval nuclear business." — Michael Fitzgerald (CFO)
Capital allocation priorities
Q (Bob Labick · CJS): Analyst asked for the top priorities for the $3 billion-plus of capital and how much is needed to hit 2030 targets versus upside. He also asked how to think about capital allocation between organic investment, M&A, and buybacks.
A: Management said the 2030 targets are anchored to 5% to 6% core CapEx and do not require specific M&A. Additional capital is for deployment opportunities above the core business; if there are no attractive options, they will return capital to shareholders and do modest buybacks in 2027. Priorities include capacity investments, Special Materials, and microreactor opportunities like Janus and BANR.
"So the way I would think about it is the 2030 targets are really anchored to the 5% to 6% core CapEx spending that we've discussed from a target standpoint." — Michael Fitzgerald (CFO)
Commercial growth and PCG integration
Q (Tomohiko Sano · JPMorgan): Analyst asked why Commercial Operations must grow about 45% for the full year and whether a large order or revenue event drives Q4. He also asked how PCG integration is tracking and whether synergies are on schedule.
A: Management said there is nothing unusual driving Q4 growth — they typically see a fourth-quarter ramp and will get contribution from PCG. They said the PCG integration is going very well, with cost opportunities found and good progress on U.S. commercial market work.
"Actually, the integration is going very, very well." — Michael Fitzgerald (CFO)
New plant decisions and CANDU role
Q (Jeffrey Campbell · Seaport): Analyst asked if starting a new U.S. heavy component facility would require firm orders like the Poland case. He also asked about CANDU making inroads in the U.S. and BWXT's potential role.
A: Management said the U.S. facility decision does not depend on firm orders and they are compelled to proceed given pipeline demand. On CANDU, they described the export opportunity and said if CANDU is built in the U.S., BWXT would be in the supply chain supplying fuel, major components, feeders, and other usual items.
"And if they do, we will certainly be in that supply chain, probably supplying fuel, major components, feeders, all the things that we normally do, we would do for that." — Rex Geveden (CEO)
2027 outlook and order timing
Q (Marc Bianchi · TD Cowen): Analyst asked about the slight upgrade to 2027 EBITDA growth and whether government or commercial drove it. He also asked which commercial reactor program could deliver orders sooner and BWXT's positioning.
A: Management said the upgrade is a refinement; they feel confident reaching high single to low double digit adjusted EBITDA and EPS, with momentum in both government and commercial. They said SMR opportunities are likely to show activity before large reactors, they are in active discussions with Westinghouse and GE, and they think orders could arrive by the end of this year or by the first half of next year.
"I think in my opinion is that the SMR opportunity is a bit ahead of large reactor opportunity." — Rex Geveden (CEO)
Government growth and AP1000 content
Q (Scott Deuschle · Deutsche Bank): Analyst asked why Government Operations organic growth has been relatively slow year-to-date and whether the revenue cadence was surprising. He also asked if South Korea funding of AP1000 builds would hurt BWXT's content opportunity and who decides supplier allocations.
A: Management said the cadence is consistent with expectations; newer program ramps (HPDU) come later in the year and strong margin performance under percent-complete accounting can reduce revenue. On AP1000s, management said they expect to compete with other global suppliers, that there should be ample opportunity, and they expect Westinghouse to make supplier decisions.
"We did discuss, I think, a little bit last quarter how we were performing actually really well on that program." — Michael Fitzgerald (CFO)
What slows FID and scaling capacity
Q (Jeffrey Grampp · Northland): Analyst asked what the main gating items are that keep new build projects from reaching FID — financing, risk allocation, or other issues. He also asked how BWXT can scale if multiple awards come and how that ranks as a concern.
A: Management said the main issue is allocation of risk among parties — who takes overruns — not financing for some deals that have sovereign funding. On scaling, they said they have expanded Cambridge capacity by about 50%, view PCG as about 50% underutilized, and plan a U.S. plant, so they are adding capacity to meet demand.
"So I think it's about the distribution of risk." — Rex Geveden (CEO)
DUECE demo and TRISO capacity
Q (Mark Shooter · William Blair): Analyst asked what metrics will judge the DUECE centrifuge prototype demo and about widening NNSA scope to include LEU and HALEU. He also asked what TRISO capacity increases are needed to meet commitments and what would trigger expansion beyond Lynchburg.
A: Management said the DUECE demo is to industrialize Oak Ridge technology, exercise the supply chain, build production capacity and a demonstration cascade, and that spinning the system will be the proof; adding LEU and HALEU to the scope is being pursued but details are ongoing. On TRISO, they said Lynchburg currently makes a couple hundred kilograms a year (enough for Pele core), they can at least quadruple Lynchburg output with improvements, and a larger greenfield needs concrete demand (e.g., Kairos/Hermes anchor, BANR orders) plus commercial HALEU availability.
"Through some technology changes and some capacity we can add and from some operational improvements, we can at least quadruple the output of that facility." — Rex Geveden (CEO)
Commercial margins and investments
Q (Laurence Alexander · Jefferies): Analyst asked how important the Commercial Operations margin improvement is for 2027 given planned investments and potential order growth, and whether that margin is a flexible part of the bridge.
A: Management said commercial margin improvement reflects mix between components and services and the contribution from PCG. They noted the divestiture of Medical removed a higher-growth, higher-margin business, so when blended with components and PCG growth, the margin shows a slight uptick driven by mix and revenue growth.
"The margin continues to perform well, and we're seeing a slight uptick primarily as a result of just kind of overall mix and growth in different aspects of the business." — Michael Fitzgerald (CFO)
Midterms and commercial order risk
Q (Andre Madrid · BTIG): Analyst asked if tomorrow's midterm elections could complicate commercial order discussions. He also asked whether missing a specific number of awards by H1 next year would risk the 2030 guidance.
A: Management said midterm elections are not a big concern because many deals are structured outside congressional appropriations and use sovereign investments or tariffs mitigation, and support for nuclear is bipartisan. They also said they have multiple ways to achieve the 2030 guidance and modest commercial order success is only one path, so missing some awards would not by itself derail the targets.
"I don't think it's a big concern, Andre, because those deals are constructed outside the framework of congressional appropriations and authorization and they don't come through the President's budget request." — Rex Geveden (CEO)
New Brunswick win and microreactor size
Q (Peter Skibitski · Alembic Global): Analyst asked for a sense of the revenue opportunity from the New Brunswick Prodigy selection and how many BANR reactors that implies. He also asked timelines and whether BWXT would supply the Navy microreactor at NSWC Crane.
A: Management declined to disclose pricing details for competitive reasons but said selling a few microreactors could be a significant revenue opportunity, though it is very early and financing and PPAs remain to be finalized. Fort Campbell is first in line; other opportunities in Wyoming, Poland, and Canada run in parallel; and the Navy Crane microreactor is a smaller unit being done by a competitor. Management emphasized their BANR is larger (22-megawatt electrical, 75 megawatts thermal) and can address bigger uses.
"But yes, I mean, if you think about selling 3 microreactors and it is a significant revenue opportunity for us and has the potential to be an exciting business for us." — Rex Geveden (CEO)
Free cash flow and working capital
Q (Joshua Korn · Wells Fargo): Analyst asked what is weighing on cash in Q4 and why guidance implies a working capital headwind into next year.
A: Management said Q4 timing follows a very strong Q3, so timing effects drive the Q4 cash position. For 2027 they cited about a $10 million headwind to pension contributions (linked to the Kinectrics acquisition), some working capital investment for growth, and timing of milestones on HPDU and enrichment programs, but underlying operating cash conversion remains good.
"One, we got about a $10 million headwind to pension contributions." — Michael Fitzgerald (CFO)
Budget delays and 2027 forecast
Q (Peter Arment · Baird): Analyst asked if unresolved budgets after midterms and continuing resolutions stretching into next year would affect their 2027 outlook.
A: Management said historically they handle continuing resolutions well because most work is on program of record and gets funded at roughly 95% of prior year, and they have uncosted carryover. They noted one program strained last year when funding ran long, but generally they are relatively immune to CRs and do not see it changing the forecast.
"Historically, we've been able to work through those continuing resolutions in pretty good shape because almost everything in our portfolio is program of record and those get funded at 95% of the prior year or whatever." — Rex Geveden (CEO)
AP1000 content and risk tolerance
Q (Michael Ciarmoli · Guggenheim): Analyst asked how much risk BWXT is willing to accept on AP1000 content and whether any terms would be too risky. He also asked if this is contemplated in the 2030 forecast.
A: Management said component manufacturing risk is familiar and acceptable — they can make RPVs, steam generators, heat exchangers, control rod drive mechanisms and accept price pressure. They distinguished that delivery/project risk is different and more problematic. They confirmed component activity is contemplated in the 2030 forecast.
"I think that's a very, very different category of risk than delivery risk." — Rex Geveden (CEO)